Table 2 Symptomatic patients in pre-COVID-19 versus COVID-19 phase
Pre COVID-19 (n = 614) | COVID-19 (n = 600) | p value | |
|---|---|---|---|
Symptomatic | 103 (16.7) | 58 (9.6) | 0.003 |
Referral (n) | NA | 58 (9.6) | |
Deranged INR | 195 (37.14) | 204 (40.31) | 0.30 |
Subtherapeutic | 137 (26.1) | 157 (31) | 0.08 |
Supratherapeutic INR < 5 | 58 (11.04) | 47 (9.2) | 0.35 |
Supratherapeutic INR > 5 | 23 (4.3) | 18 (3.5) | 0.52 |
Clinical events | |||
Hospitalization | 29 (4.7) | 19 (3.1) | 0.18 |
Major bleeding | 7 (1.1) | 3 (0.5) | 0.34 |
Minor bleeding | 4 (0.6) | 5 (0.8) | 0.75 |
Thromboembolic episode | 15 (2.4) | 10 (1.6) | 0.42 |
CVA/TIA | 11 (1.7) | 7 (1.1) | 0.77 |
Prosthetic valve thrombosis | 4 (0.6) | 3 (0.5) | 1.00 |